Contraception and risk of meningiom: new recommendations

On December 18, 2024, the French National Agency for the Safety of Medicines and Health Products (ANSM) issued new recommendations for the use and monitoring of women using contraception based on desogestrel. The recommendations are based on an increased risk of meningioma associated with oral contraceptives containing desogestrel alone, particularly in women over 45 years or those using it for more than 5 years, which is considered very low but warrants a brain MRI scan only in case of suspicious symptoms or prolonged exposure to progestatins.